

21 September 2016

New Study: Faulding GlucoControl Improves Long-Term Glycaemic Control

Highlights

- University of Adelaide reveals a new global breakthrough for Faulding® GlucoControl™ for the management of type 2 diabetes
- For the first time, a non-pharmaceutical, natural food-based product has demonstrated it can significantly reduce the dangerous blood sugar spikes after a standard meal (converting meals to be “low GI”) and improve overall glycaemic control (HbA1c) in the long term
- Faulding® GlucoControl™ recently featured in Australian media

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omniblend Innovation Pty Ltd, the medical technology company focused on foods for special medical purposes.

Study Results

A new research study conducted by experts at the University of Adelaide reveals a new breakthrough in the management of type 2 diabetes – one of the world’s fastest growing diseases.

The findings were presented at The European Association for the Study of Diabetes (EASD) Annual Meeting in Germany, reveal that for the first time, Faulding® GlucoControl™, a non-pharmaceutical, natural food-based product can significantly reduce the dangerous blood sugar spikes after a standard meal and improve overall glycaemic control (HbA1c) in the long term.

“Glycaemic control is critical in reducing the risk of complications from type 2 diabetes, which is why these results are compelling,” said Dr Chris Rayner, a Gastroenterologist involved in the study and a Professor at the University of Adelaide.

“Better control of blood glucose, as reflected not only in HbA1c but also in the rise in blood glucose after meals, helps prevent or delay the serious complications that can develop in type 2 diabetes, which include vision impairment, vascular damage and even amputations.”

“A dietary approach to controlling blood glucose has enormous appeal to the broad community of people living with type 2 diabetes,” added Dr. Rayner.

According to dataⁱ from Diabetes Australia more than 4,400 diabetes-related amputations are performed at Australian hospitals every year. Experts estimate that spending on diabetes-related amputations, and other costs related to diabetic foot disease, costs Australia around \$875 million every single year.

“The likelihood that type 2 diabetes impacts you, or someone you love, is greater than ever. Diabetes cannot be cured but with proper management, we can reduce the severity and likelihood of its serious consequences,” said preventative health expert Dr Ross Walker.

“Having a product that can reduce or maintain blood sugar levels easily available in stores will be a game-changer in encouraging people to take better control of their diabetes,” added Dr. Walker.

Omniblend Innovation’s pre meal shake is a result of six years and more than \$5 million in research and development. Clinical trials show it reduces the Glycaemic Index (GI) of food and drink and controls the spikes in blood glucose which, over time, cause damage associated with this disease.

“While people can live a long life with type 2 diabetes, proper management is critical to avoiding its serious outcomes. For us, that meant making a product that is both safe and effective and also enjoyable for people to consume every day. No intervention is effective if compliance is low so we were pleased to see the results confirmed that participants had no trouble incorporating our product into their lifestyles for the full 12 weeks,” said Arie Nudel, Managing Director, Omniblend Innovation.

Recent Media

Faulding® GlucoControl™ has recently been profiled in an article in The Australian’s health section on 19 September. Additionally, Dr. Ross Walker presented a segment on the benefits of the product on the Nine Network’s The Today Show, on 20 September.

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

About Omniblend Innovation

Omniblend Innovation is a private Melbourne based company developing evidence-based dietary interventions to improve the lives of people with common chronic diseases such type-2 diabetes and low blood pressure (hypotension).

In August 2016 the Company launched its maiden product, Faulding® GlucoControl™ for use in the dietary management of type 2 diabetes and pre-diabetes.

For more information, please visit www.obinnovation.com.au

For more information:

Ben Rohr
Investment Director
+61 8 6465 5500
benr@eveinvestments.com.au

<https://www.diabetesaustralia.com.au/news/15266?type=articles>